Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis

BACKGROUND: Sodium-glucose co-transporter-2 inhibitors (SGLT-2is) are licenced for initiation for glucose lowering in people with type 2 diabetes (T2DM) with an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m(2)). However, recent trial data have shown that these medications have renal...

Descripción completa

Detalles Bibliográficos
Autores principales: Hinton, William, Feher, Michael D., Munro, Neil, Joy, Mark, de Lusignan, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237469/
https://www.ncbi.nlm.nih.gov/pubmed/34183018
http://dx.doi.org/10.1186/s12933-021-01316-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237469/
https://www.ncbi.nlm.nih.gov/pubmed/34183018
http://dx.doi.org/10.1186/s12933-021-01316-4

Ejemplares similares